Evidence map›Paper›PMID 37678674›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2023

Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma.

Pingjun Chen, Frank R Rojas, Xin Hu, Alejandra Serrano, Bo Zhu, Hong Chen, Lingzhi Hong, Rukhmini Bandyoyadhyay, Muhammad Aminu, Neda Kalhor and 18 more

Open access · hybridAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Inhaled Pollutants of the Gero-Exposome and Later-Life Health.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 3 countries.

Pingjun ChenDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: pchen6@mdanderson.org.
Frank R RojasDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xin HuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alejandra SerranoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bo ZhuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hong ChenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lingzhi HongDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rukhmini BandyoyadhyayDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Muhammad AminuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Neda KalhorDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Siba El HusseinDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.
Joseph D KhouryDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.
Harvey I PassDepartment of Surgery, NYU Langone Health, New York, New York.
Andre L MoreiraDepartment of Pathology, NYU Langone Health, New York, New York.
Vamsidhar VelchetiDepartment of Medicine, NYU Grossman School of Medicine, New York, New York.
Daniel H StermanDepartment of Medicine, NYU Grossman School of Medicine, New York, New York; Department of Cardiothoracic Surgery, NYU Grossman School of Medicine, New York, New York.
Junya FukuokaDepartment of Pathology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Kazuhiro TabataDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Dan SuCancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Lisha YingCancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Luisa M Solis SotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianjun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jzhang20@mdanderson.org.
Jia WuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jwu11@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USNew York University · USNYU Langone Health · USZhejiang Cancer Hospital · CNKagoshima University · JPNagasaki University · JPUniversity of Nebraska Medical Center · USUniversity of Rochester Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancerR01CA276178 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Natalie Vokes, Jia Wu · 2023 to 2026
$2.6M
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinomaR01CA234629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHANG, JIANJUN · 2019 to 2023
$1.8M
QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCERR00CA218667 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, JIA · 2020 to 2022
$747k
BLRD VA IK6 BX006185NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R00 CA218667NCI NIH HHS R01 CA234629NCI NIH HHS R01 CA276178
6 · The paper itself

Abstract

Recent statistics on lung cancer, including the steady decline of advanced diseases and the dramatically increasing detection of early-stage diseases and indeterminate pulmonary nodules, mark the significance of a comprehensive understanding of early lung carcinogenesis. Lung adenocarcinoma (ADC) is the most common histologic subtype of lung cancer, and atypical adenomatous hyperplasia is the only recognized preneoplasia to ADC, which may progress to adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) and eventually to invasive ADC. Although molecular evolution during early lung carcinogenesis has been explored in recent years, the progress has been significantly hindered, largely due to insufficient materials from ADC precursors. Here, we employed state-of-the-art deep learning and artificial intelligence techniques to robustly segment and recognize cells on routinely used hematoxylin and eosin histopathology images and extracted 9 biology-relevant pathomic features to decode lung preneoplasia evolution. We analyzed 3 distinct cohorts (Japan, China, and United States) covering 98 patients, 162 slides, and 669 regions of interest, including 143 normal, 129 atypical adenomatous hyperplasia, 94 AIS, 98 MIA, and 205 ADC. Extracted pathomic features revealed progressive increase of atypical epithelial cells and progressive decrease of lymphocytic cells from normal to AAH, AIS, MIA, and ADC, consistent with the results from tissue-consuming and expensive molecular/immune profiling. Furthermore, pathomics analysis manifested progressively increasing cellular intratumor heterogeneity along with the evolution from normal lung to invasive ADC. These findings demonstrated the feasibility and substantial potential of pathomics in studying lung cancer carcinogenesis directly from the low-cost routine hematoxylin and eosin staining.

Indexed as

AdenocarcinomaAdenocarcinoma in SituLung NeoplasmsPrecancerous ConditionsArtificial IntelligenceCarcinogenesisEosine Yellowish-(YS)Evolution, MolecularHematoxylinHumansHyperplasiaLungEosine Yellowish-(YS)Hematoxylinartificial intelligencecomputational pathologydeep learninglung cancerpathomic featurespreneoplasia evolutiontumor heterogeneity

Identifiers

PMID37678674
PMCPMC10841057
OpenAlexW4386530891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.